Literature DB >> 31103810

Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study.

Laura Kranaster1, Kaj Blennow2, Henrik Zetterberg3, Alexander Sartorius4.   

Abstract

BACKGROUND: Several lines of evidence are pointing towards an involvement of the vascular endothelial growth factor (VEGF) in the pathophysiology of depression. There are studies analyzing blood levels of VEGF in patients with depression compared to controls, but a data on cerebrospinal fluid (CSF) levels of VEGF in patients with depression are lacking.
METHOD: CSF VEGF levels were measured in patients (n = 12) with a severe, treatment-resistant depressive episode before and after the antidepressant treatment by a course of electroconvulsive therapy (ECT) and compared to age- and sex-matched controls (n = 20).
RESULTS: The patients with depression showed lower mean VEGF levels in the CSF prior to ECT than the controls (p = 0.041). Regarding the patients, CSF VEGF concentration at baseline and after the complete ECT treatment did not differ from each other (p = 0.78). LIMITATIONS: Major limitations of this study are the small sample size and that data from corresponding serum levels cannot be provided. Another limitation is that the controls were not completely healthy, as they were recruited from a memory clinic with subjective complaints. The timing of the second sample might have been suboptimal, when taking into account that there might be an on-going phase of re-equilibrating after ECT.
CONCLUSIONS: CSF VEGF concentrations were lower in a clinical sample of patients with treatment-resistant depression compared with matched controls. Additionally, no change in CSF VEGF levels during a course of ECT could be detected.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31103810     DOI: 10.1016/j.jad.2019.04.080

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder.

Authors:  Meysam Amidfar; Gislaine Zilli Réus; Airam Barbosa de Moura; João Quevedo; Yong-Ku Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation.

Authors:  Monika Elemery; Szilvia Kiss; Peter Dome; Laszlo Pogany; Gabor Faludi; Judit Lazary
Journal:  Front Psychiatry       Date:  2022-05-31       Impact factor: 5.435

Review 3.  Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.

Authors:  Satoshi Deyama; Ronald S Duman
Journal:  Pharmacol Biochem Behav       Date:  2019-12-09       Impact factor: 3.533

Review 4.  Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.

Authors:  Ronald S Duman; Satoshi Deyama; Manoela Viar Fogaça
Journal:  Eur J Neurosci       Date:  2019-12-20       Impact factor: 3.386

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.